Lu-177-DOTA-Octreotide

Phase 2Peptide

Lu-177-DOTA-Octreotide is one of 32 small molecule programs targeting Neuroendocrine Neoplasm. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Neuroendocrine NeoplasmRecruiting

Neuroendocrine NeoplasmPhase 2

Recruiting

Competition

Competitive Landscape

31 competitors in Neuroendocrine Neoplasm

#DrugCompanyPhaseTrials

Kisqali

Afinitor

Talzenna

Arava

Lenvima

Lynparza

Nolvadex

Sandostatin

Farydak

Tarceva

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Study completion

NCT04917484

Clinical

Trials by Indication[1]

Unspecified1 trial

Dosimetry Based PRRT Versus Standard Dose PRRT With Lu-177-DOTATOC in NEN Patients

Recruiting·TTine Gregersen, MD·Phase 2·NCT04917484·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Lu-177-DOTA-Octreotide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lu-177-DOTA-Octreotide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lu-177-DOTA-Octreotide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tine Gregersen, MD company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Peptide[2]
Highest Phase: Phase 2[1]
Company: TTine Gregersen, MD

Lu-177-DOTA-Octreotide

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Unspecified1 trial

References

Drug Info

Quick Facts

Related News